JO3270B1 - مشتقات كوينولين بصفة عوامل مضادة للبكتيريا - Google Patents

مشتقات كوينولين بصفة عوامل مضادة للبكتيريا

Info

Publication number
JO3270B1
JO3270B1 JOP/2006/0189A JOP20060189A JO3270B1 JO 3270 B1 JO3270 B1 JO 3270B1 JO P20060189 A JOP20060189 A JO P20060189A JO 3270 B1 JO3270 B1 JO 3270B1
Authority
JO
Jordan
Prior art keywords
alkyl
alky1
hydrogen
alkylthio
halo
Prior art date
Application number
JOP/2006/0189A
Other languages
English (en)
Inventor
Koul Anil
Emile Georges Guillemont Jerome
Jozef Lodewijk Marcel Andries Koenraad
Madeleine Simone Motte Magali
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Application granted granted Critical
Publication of JO3270B1 publication Critical patent/JO3270B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/36—Sulfur atoms

Abstract

يتعلق الاختراع الحالي باستخدام مركب (compound) لتصنيع دواء (medicament) لمعالجة عدوى بكتيرية (bacterial infection) بشرط ان تكون العدوى البكترية ( bacterial infection) خلاف العدوى البكتيرية الفطرية (Mycobacterial infection) ويكون المركب المذكور هو مركب من الصيغة ( Ia) او ( Ib) : ملح اضافي حمض او قاعدة (acid or base addition salt) مقبول دوائيا منه، شكل ايزومري فراغي كيماوئيا (stereochemically isomeric form) منه شكل توتومري (tautomeric form) منه او N اوكسيد ( N- oxide) منه ، حيث يكون R1 هو هيدروجين ( HYDROGEN) ، هالو ( halo) هالو الكيل ( haloalky1) ، سيانو (cyano) ، هيدروكسي (haloalky) Ar، Het، الكيل (alky1) الكيل اوكسي (alkyloxy) ، الكيل ثيو (alkylthio) ، الكيل اوكسي الكيل ( alkyloxyalky1) الكيل ثيو الكيل (alkyloxyalky1) ، Ar- الكيل ( Ar- alky1) او ثنائي (Ar) الكيل (di(Aralky1) ; p هو 1 الى 4 R2 هو هيدروجين (hydrogen) هيدروكسي (hydroxy) مركابتو (mercapto) الكيل اوكسي (alkyloxy) الكيل اوكسي اوكسي (alkyloxyalkyloxy) الكيل ثيو (alkylthio) احادي او ثنائي (الكيل ) امينو (mono or di(alky1 )amino) او حيث يكون Y هو CH2، O، S NH او N الكيل (N- alky1) R3 هو Ar او Het R5 R4 كل منهما على حدة يكون هيدروجين( hydrogen)، الكيل (alky1) او بنزيل (benzy1) او يؤخذ R4 و R5 معا مع ذرة N المرتبطة معهما؛ R6 هو هيدروجين (hydrogen) هالو (halo) هالو الكيل (haloalky1) هيدروكسي ( hydroxy) Ar ، الكيل (alky1) الكيل اوكسي (alkyloxy) الكيل ثيو (alkylthio) الكيل اوكسي الكيل (alkyloxyalky1) ، الكيل ثيو الكيل (alkylthioalky1) Ar -الكيل (Ar-alky1) او ثنائي (Ar) الكيل (di(Ar)alky1) او قد يؤخذ شقا R6 المتجاوران معا لتشكيل CH=CH-CH=CH- -؛ r هو 1 الى 5؛ R7 هو هيدروجين (HYDROGEN) الكيل (alky1) ، R9 او Het ،R8 هو هيدروجين (HYDROGEN) او الكيل (alky1) R9 هو اوكسو (OXO)؛ او R8 و R9 معا يشكلان = CH=CH-N-؛ Alk هوشق هيدروكربون (hydrocarbon radical) مشبع مستقيم او متفرغ له من 1الى 6 ذرات كربون carbon.
JOP/2006/0189A 2005-06-28 2006-06-25 مشتقات كوينولين بصفة عوامل مضادة للبكتيريا JO3270B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05105769 2005-06-28

Publications (1)

Publication Number Publication Date
JO3270B1 true JO3270B1 (ar) 2018-09-16

Family

ID=35445742

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2006/0189A JO3270B1 (ar) 2005-06-28 2006-06-25 مشتقات كوينولين بصفة عوامل مضادة للبكتيريا

Country Status (34)

Country Link
US (2) US20100204270A1 (ar)
EP (1) EP1898910B1 (ar)
JP (1) JP5193859B2 (ar)
KR (1) KR101423229B1 (ar)
CN (1) CN101252928B (ar)
AP (1) AP2733A (ar)
AR (1) AR057654A1 (ar)
AU (1) AU2006263884B2 (ar)
BR (1) BRPI0612534B8 (ar)
CA (1) CA2612623C (ar)
CY (1) CY1118515T1 (ar)
DK (1) DK1898910T3 (ar)
EA (1) EA014163B1 (ar)
ES (1) ES2606772T3 (ar)
HK (1) HK1120734A1 (ar)
HR (1) HRP20161704T1 (ar)
HU (1) HUE031268T2 (ar)
IL (1) IL188394A (ar)
JO (1) JO3270B1 (ar)
LT (1) LT1898910T (ar)
ME (1) ME02690B (ar)
MX (1) MX2008000082A (ar)
MY (1) MY151030A (ar)
NO (1) NO341283B1 (ar)
NZ (1) NZ564339A (ar)
PL (1) PL1898910T3 (ar)
PT (1) PT1898910T (ar)
RS (1) RS55408B1 (ar)
SG (1) SG166799A1 (ar)
SI (1) SI1898910T1 (ar)
TW (1) TWI392494B (ar)
UA (1) UA91549C2 (ar)
WO (1) WO2007000436A1 (ar)
ZA (1) ZA200711149B (ar)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9790186B2 (en) 2009-07-21 2017-10-17 Trustees Of Dartmouth College Composition and method for prevention, mitigation or treatment of an enteropathogenic bacterial infection
EP2841425B1 (en) 2012-04-27 2016-03-23 Janssen Pharmaceutica, N.V. Antibacterial quinoline derivatives
ES2607879T3 (es) 2012-04-27 2017-04-04 Janssen Pharmaceutica N.V. Derivados de quinolina antibacterianos
CN105037497B (zh) * 2015-03-27 2018-06-26 中牧实业股份有限公司 一种恩拉霉素的提纯方法
WO2017035288A1 (en) * 2015-08-27 2017-03-02 Trustees Of Dartmouth College Composition and method for prevention, mitigation or treatment of an enteropathogenic bacterial infection

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6103905A (en) * 1997-06-19 2000-08-15 Sepracor, Inc. Quinoline-indole antimicrobial agents, uses and compositions related thereto
DE19937116A1 (de) * 1999-08-06 2001-02-08 Bayer Ag Moxifloxacin Kochsalzformulierung
SI2301544T1 (sl) * 2002-07-25 2013-01-31 Janssen Pharmaceutica, N.V. Derivati kinolina kot vmesne spojine za mikobakterijske inhibitorje
JP5081617B2 (ja) * 2004-05-28 2012-11-28 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 薬剤耐性マイコバクテリア性疾患の処置のための置換キノリン誘導体の使用
EE05394B1 (et) * 2004-12-24 2011-04-15 Janssen Pharmaceutica N.V. Kinoliinihendid kasutamiseks latentse tuberkuloosi ravis

Also Published As

Publication number Publication date
BRPI0612534B1 (pt) 2020-04-22
NO20080481L (no) 2008-02-29
AU2006263884B2 (en) 2013-01-10
EP1898910B1 (en) 2016-09-28
BRPI0612534A2 (pt) 2010-11-23
CA2612623C (en) 2016-09-27
CA2612623A1 (en) 2007-01-04
ES2606772T3 (es) 2017-03-27
BRPI0612534B8 (pt) 2021-05-25
JP2008546825A (ja) 2008-12-25
MX2008000082A (es) 2008-03-24
IL188394A0 (en) 2008-08-07
EA014163B1 (ru) 2010-10-29
KR20080028460A (ko) 2008-03-31
AP2733A (en) 2013-09-30
BRPI0612534A8 (pt) 2017-12-26
UA91549C2 (ru) 2010-08-10
AU2006263884A1 (en) 2007-01-04
IL188394A (en) 2012-09-24
RS55408B1 (sr) 2017-04-28
MY151030A (en) 2014-03-31
CY1118515T1 (el) 2017-07-12
AR057654A1 (es) 2007-12-12
ZA200711149B (en) 2009-06-24
US20130030017A1 (en) 2013-01-31
TW200738237A (en) 2007-10-16
TWI392494B (zh) 2013-04-11
HRP20161704T1 (hr) 2017-02-10
SG166799A1 (en) 2010-12-29
HK1120734A1 (en) 2009-04-09
NO341283B1 (no) 2017-10-02
ME02690B (me) 2017-10-20
EA200800152A1 (ru) 2008-06-30
CN101252928B (zh) 2012-05-23
HUE031268T2 (en) 2017-06-28
US20100204270A1 (en) 2010-08-12
DK1898910T3 (en) 2017-01-09
WO2007000436A1 (en) 2007-01-04
PT1898910T (pt) 2016-11-16
CN101252928A (zh) 2008-08-27
JP5193859B2 (ja) 2013-05-08
KR101423229B1 (ko) 2014-07-25
LT1898910T (lt) 2017-01-10
PL1898910T3 (pl) 2017-03-31
SI1898910T1 (sl) 2017-01-31
EP1898910A1 (en) 2008-03-19
NZ564339A (en) 2011-02-25

Similar Documents

Publication Publication Date Title
TW200744594A (en) Quinoline derivatives as antibacterial agents
TW200744595A (en) Quinoline derivatives as antibacterial agents
PE20061305A1 (es) Compuestos derivados de fenilacetamidas como inhibidores de proteincinasas
RS20090249A (en) Spiroketone acetyl-coa carboxylase inhibotors
TW200637551A (en) Treatment of latent tuberculosis
HK1138262A1 (en) Novel phosphodiesterase inhibitors
WO2005070924A8 (en) Substituted quinolines and their use as mycobacterial inhibitors
JO3322B1 (ar) مشتقات كوينولين بصفة عوامل مضادة للبكتيريا
CY1113535T1 (el) Παραγωγα κινολινης ως αντιβακτηριακοι παραγοντες
JO3270B1 (ar) مشتقات كوينولين بصفة عوامل مضادة للبكتيريا
MY153291A (en) Quinoline derivatives as antibacterial agents
JO2695B1 (ar) معالجة السل الكامن
TW200738637A (en) Compounds having activity at NK3 receptor and uses thereof in medicine